[go: up one dir, main page]

WO2000053013A8 - Inhibition de la pkc afin de traiter les insuffisances de permeabilite - Google Patents

Inhibition de la pkc afin de traiter les insuffisances de permeabilite

Info

Publication number
WO2000053013A8
WO2000053013A8 PCT/US2000/006405 US0006405W WO0053013A8 WO 2000053013 A8 WO2000053013 A8 WO 2000053013A8 US 0006405 W US0006405 W US 0006405W WO 0053013 A8 WO0053013 A8 WO 0053013A8
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
inhibition
treat
permeability
failure
Prior art date
Application number
PCT/US2000/006405
Other languages
English (en)
Other versions
WO2000053013A1 (fr
Inventor
George Liang King
Original Assignee
Joslin Diabetes Center Inc
George Liang King
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, George Liang King filed Critical Joslin Diabetes Center Inc
Priority to AU36252/00A priority Critical patent/AU3625200A/en
Publication of WO2000053013A1 publication Critical patent/WO2000053013A1/fr
Publication of WO2000053013A8 publication Critical patent/WO2000053013A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode permettant de traiter un patient présentant une disjonction de perméabilité. Cette méthode consiste à administrer au fluide de dialyse péritonéale un inhibiteur de PKC (protéinekinase C), notamment la PKC β, puis à administrer ce fluide de dialyse à un patient souffrant d'insuffisance rénale. L'invention concerne également un fluide de dialyse péritonéale amélioré ainsi que des méthodes de fabrication de ce.
PCT/US2000/006405 1999-03-12 2000-03-10 Inhibition de la pkc afin de traiter les insuffisances de permeabilite WO2000053013A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36252/00A AU3625200A (en) 1999-03-12 2000-03-10 Inhibition of pkc to treat permeability failure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12404399P 1999-03-12 1999-03-12
US60/124,043 1999-03-12

Publications (2)

Publication Number Publication Date
WO2000053013A1 WO2000053013A1 (fr) 2000-09-14
WO2000053013A8 true WO2000053013A8 (fr) 2001-04-05

Family

ID=22412423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006405 WO2000053013A1 (fr) 1999-03-12 2000-03-10 Inhibition de la pkc afin de traiter les insuffisances de permeabilite

Country Status (2)

Country Link
AU (1) AU3625200A (fr)
WO (1) WO2000053013A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists

Also Published As

Publication number Publication date
AU3625200A (en) 2000-09-28
WO2000053013A1 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
WO2003059378A3 (fr) Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
SE9503562L (sv) Kateter, särskilt för peritonealdialys
WO2001005392A3 (fr) Traitement des douleurs chroniques par des inhibiteurs de mek
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
WO2001005390A3 (fr) Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
ATE329672T1 (de) Hämodiafiltration/hämofiltrations-patronen
DE60128705D1 (de) Vorrichtung zur verminderung von erhöhtem lungenvenendruck
WO2006042100A3 (fr) Procede permettant le traitement d'une maladie polykystique des reins
WO2002028353A3 (fr) Inhibiteur du transport de phosphate
WO2001081343A3 (fr) Composes permettant de traiter la fibromyalgie et le syndrome de fatigue chronique
WO2003047341A3 (fr) Systemes et procedes antimicrobiens
WO2002006513A3 (fr) Procede de traitement des virus de l'herpes
WO2002005642A3 (fr) Compositions biocides a melange synergique de glutaraldehyde et de 2,2-dibromo-3-nitrilo propionamide, et utilisation correspondante
WO2002020013A3 (fr) Methode de traitement d'allergies au moyen de pyrazoles substitues
WO2000052134A3 (fr) Inhibiteurs de la prenyle-proteine transferase
WO2004104019A3 (fr) Anti-inflammatory/anti-microbial peptides for use in dialysis
WO2001060458A3 (fr) Inhibiteurs de la prenyl-proteine transferase
WO2000053013A8 (fr) Inhibition de la pkc afin de traiter les insuffisances de permeabilite
AU2001232053A1 (en) System for the extracorporeal treatment of blood
WO2000021516A3 (fr) Procedes destines a empecher des complications diabetiques
WO2002028433A3 (fr) Medicaments
WO2002083112A3 (fr) Methode de traitement de la polykystose renale
WO1999066912A3 (fr) Traitement de l'hypertension arterielle pulmonaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase